title: Suppression of Th2-driven airway inflammation by allergen immunotherapy is independent of B cell and Ig responses in mice.
abstract: Allergen-specific immunotherapy (IT) uniquely renders long-term relief from allergic symptoms and is associated with elevated serum levels of allergen-specific IgG and IgA. The allergen-specific IgG response induced by IT treatment was shown to be critical for suppression of the immediate phase of the allergic response in mice, and this suppression was partially dependent on signaling through FcγRIIB. To investigate the relevance of the allergen-specific IgG responses for suppression of the Th2-driven late-phase allergic response, we performed IT in a mouse model of allergic asthma in the absence of FcγRIIB or FcγRI/FcγRIII signaling. We found that suppression of Th2 cell activity, allergic inflammation, and allergen-specific IgE responses is independent of FcγRIIB and FcγRI/FcγRIII signaling. Moreover, we show that the IT-induced allergen-specific systemic IgG or IgA responses and B cell function are dispensable for suppression of the late-phase allergic response by IT treatment. Finally, we found that the secretory mucosal IgA response also is not required for suppression of the Th2-driven allergic inflammation by IT. These data are in contrast to the suppression of the immediate phase of the allergic response, which is critically dependent on the induced allergen-specific serum IgG response. Hence, IT-induced suppression of the immediate and late phases of the allergic response is governed by divergent and independent mechanisms. Our data show that the IT-induced suppression of the Th2 cell-dependent late-phase allergic response is independent of the allergen-specific IgG and IgA responses that are associated with IT treatment.
authors.affiliation: Laboratory of Allergology and Pulmonary Diseases, Department of Pathology and Medical Biology, Groningen Research Institute for Asthma and COPD Research, University Medical Center Groningen, University of Groningen, Groningen;
authors.forename: Soheila
authors.initials: S
authors.lastname: Shirinbak
authors.forename: Yousef A
authors.initials: YA
authors.lastname: Taher
authors.forename: Hadi
authors.initials: H
authors.lastname: Maazi
authors.forename: Renée
authors.initials: R
authors.lastname: Gras
authors.forename: Betty C A M
authors.initials: BC
authors.lastname: van Esch
authors.forename: Paul A J
authors.initials: PA
authors.lastname: Henricks
authors.forename: Janneke N
authors.initials: JN
authors.lastname: Samsom
authors.forename: J Sjef
authors.initials: JS
authors.lastname: Verbeek
authors.forename: Bart N
authors.initials: BN
authors.lastname: Lambrecht
authors.forename: Antoon J M
authors.initials: AJ
authors.lastname: van Oosterhout
authors.forename: Martijn C
authors.initials: MC
authors.lastname: Nawijn
mesh_terms: D000485:Allergens / Q000276:immunology; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism; D003888:Desensitization, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D007108:Immune Tolerance / Q000276:immunology*; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011014:Pneumonia / Q000276:immunology* / Q000517:prevention & control; D017452:Receptors, IgG / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology*
chemical_list: D000485:Allergens; D016207:Cytokines; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D017452:Receptors, IgG